Duke University Engineers Develop AI Platform to Target “Undruggable” Diseases

In a groundbreaking study published on January 22 in Science Advances, biomedical engineers from Duke University have unveiled an innovative AI-based platform designed to create short proteins, or peptides, that can bind to and neutralize proteins associated with diseases previously considered untreatable. This new technology, inspired by OpenAI’s advancements in image generation models, offers a promising approach to drug development for challenging medical conditions.

The algorithm developed by the Duke team efficiently generates peptides and prioritizes them for experimental testing, speeding up the process of drug discovery. By focusing on disease-causing proteins that traditional drugs cannot target effectively, this AI platform opens new avenues for treating severe illnesses.

Date: January 22, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Tests on Sunglasses Show Deficiencies in Protection Against Ultraviolet Rays Breakthrough AI Tool Identifies Life-Saving Medication for Rare Disease Patient Access to Free COVID-19 Tests in the United States How the Brain Rewires Itself for Language Recovery After a Stroke

Author

Mark Chiang

Ph.D in Biomedical Informatics Head of AI at GeneOnline